Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Roche will advance discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform and will have exclusive rights to specific targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,042.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration January 03, 2024
Details:
Under the terms of the agreement, Remix will receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for products. In exchange, Janssen will have exclusive rights to three specific targets with applications in immunology and oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $1,045.0 million Upfront Cash: $45.0 million
Deal Type: Collaboration February 17, 2022
Details:
The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.
Lead Product(s): RNA processing targeted therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foresite Capital
Deal Size: $81.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 08, 2020